Antibody prevalence above 90% months after receiving second dose
Reuter
The Indian vaccine Covishield (known as Oxford/AstraZeneca in the UK) can provide high levels of protection against Covid-19 infections, according to a new study.
A recent analysis done on 500 healthcare workers by Pune-based BJMC and Sassoon hospital revealed that the participants showed high levels of protection (seroprevalence) even three to seven months after taking two doses of Covishield, according to a Times of India report.
ALSO READ
The study also found that the antibody prevalence in the participants was above 90% months after receiving their second dose.
A booster shot was, however, advised by doctors. A third top-up dose does boost immunity against the new variant, based on an analysis of data from hundreds of Omicron cases.